This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shi, X. Articles by Mueller, B. M. Search for Related Content PubMed PubMed Citation Articles by Shi, X. Articles by Mueller, B. M.

---

Angiogenesis, Metastasis, and the Cellular Microenvironment

Protease-Activated Receptors (PAR1 and PAR2) Contribute to Tumor Cell Motility and Metastasis¹

¹ Cancer Biology Division, La Jolla Institute for Molecular Medicine, San Diego, California; ² Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and ³ Department of Immunology, Scripps Research Institute, La Jolla, California

Requests for reprints: Barbara M. Mueller, Cancer Biology Division, La Jolla Institute for Molecular Medicine, 4570 Executive Drive, San Diego, CA 92121. Phone: 858-587-8788; Fax: 858-587-6742. E-mail: bmueller{at}ljimm.org

The effects of the pleiotropic serine protease thrombin on tumor cells are commonly thought to be mediated by the thrombin receptor protease-activated receptor 1 (PAR1). We demonstrate here that PAR1 activation has a role in experimental metastasis using the anti-PAR1 antibodies ATAP2 and WEDE15, which block PAR1 cleavage and activation. Thrombin also stimulates chemokinesis of human melanoma cells toward fibroblast conditioned media and soluble matrix proteins. Thrombin-enhanced migration is abolished by anti-PAR1 antibodies, demonstrating that PAR1 cleavage and activation are required. The PAR1-specific agonist peptide TFLLRNPNDK, however, does not stimulate migration, indicating that PAR1 activation is not sufficient. In contrast, a combination of TFLLRNPNDK and the PAR2 agonist peptide SLIGRL mimics the thrombin effect on migration, whereas PAR2 agonist alone has no effect. Agonist peptides for the thrombin receptors PAR3 and PAR4 used alone or with PAR1 agonist also have no effect. Similarly, activation of PAR1 and PAR2 also enhances chemokinesis of prostate cancer cells. Desensitization with PAR2 agonist abolishes thrombin-enhanced cell motility, demonstrating that thrombin acts through PAR2. PAR2 is cleaved by proteases with trypsin-like specificity but not by thrombin. Thrombin enhances migration in the presence of a cleavage-blocking anti-PAR2 antibody, suggesting that thrombin activates PAR2 indirectly and independent of receptor cleavage. Treatment of melanoma cells with trypsin or PAR2 agonist peptide enhances experimental metastasis. Together, these data confirm a role for PAR1 in migration and metastasis and demonstrate an unexpected role for PAR2 in thrombin-dependent tumor cell migration and in metastasis.

This article has been cited by other articles:

				G. J. Mize, W. Wang, and T. K. Takayama Prostate-Specific Kallikreins-2 and -4 Enhance the Proliferation of DU-145 Prostate Cancer Cells through Protease-Activated Receptors-1 and -2 Mol. Cancer Res., June 1, 2008; 6(6): 1043 - 1051. [Abstract] [Full Text] [PDF]

				A. R. Radjabi, K. Sawada, S. Jagadeeswaran, A. Eichbichler, H. A. Kenny, A. Montag, K. Bruno, and E. Lengyel Thrombin Induces Tumor Invasion through the Induction and Association of Matrix Metalloproteinase-9 and {beta}1-Integrin on the Cell Surface J. Biol. Chem., February 1, 2008; 283(5): 2822 - 2834. [Abstract] [Full Text] [PDF]

				I Jahan, J Fujimoto, S. M. Alam, E Sato, H Sakaguchi, and T Tamaya Role of protease activated receptor-2 in tumor advancement of ovarian cancers Ann. Onc., September 1, 2007; 18(9): 1506 - 1512. [Abstract] [Full Text] [PDF]

				C. E. Hamill, W. M. Caudle, J. R. Richardson, H. Yuan, K. D. Pennell, J. G. Greene, G. W. Miller, and S. F. Traynelis Exacerbation of Dopaminergic Terminal Damage in a Mouse Model of Parkinson's Disease by the G-Protein-Coupled Receptor Protease-Activated Receptor 1 Mol. Pharmacol., September 1, 2007; 72(3): 653 - 664. [Abstract] [Full Text] [PDF]

				C. R. Evelyn, S. M. Wade, Q. Wang, M. Wu, J. A. Iniguez-Lluhi, S. D. Merajver, and R. R. Neubig CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling Mol. Cancer Ther., August 1, 2007; 6(8): 2249 - 2260. [Abstract] [Full Text] [PDF]

				H. Uusitalo-Jarvinen, T. Kurokawa, B. M. Mueller, P. Andrade-Gordon, M. Friedlander, and W. Ruf Role of Protease Activated Receptor 1 and 2 Signaling in Hypoxia-Induced Angiogenesis Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1456 - 1462. [Abstract] [Full Text] [PDF]

				J. N. McLaughlin, M. M. Patterson, and A. B. Malik Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization PNAS, March 27, 2007; 104(13): 5662 - 5667. [Abstract] [Full Text] [PDF]

				P. Kelly, L. N. Stemmle, J. F. Madden, T. A. Fields, Y. Daaka, and P. J. Casey A Role for the G12 Family of Heterotrimeric G Proteins in Prostate Cancer Invasion J. Biol. Chem., September 8, 2006; 281(36): 26483 - 26490. [Abstract] [Full Text] [PDF]

				T. Goerge, A. Barg, E.-M. Schnaeker, B. Poppelmann, V. Shpacovitch, A. Rattenholl, C. Maaser, T. A. Luger, M. Steinhoff, and S. W. Schneider Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res., August 1, 2006; 66(15): 7766 - 7774. [Abstract] [Full Text] [PDF]

				W. Ruf Flow perturbation is linked to endothelial par signaling. Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 962 - 964. [Full Text] [PDF]

				M. Belting, J. Ahamed, and W. Ruf Signaling of the Tissue Factor Coagulation Pathway in Angiogenesis and Cancer Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1545 - 1550. [Abstract] [Full Text] [PDF]

				N Vergnolle CLINICAL RELEVANCE OF PROTEINASE ACTIVATED RECEPTORS (PARS) IN THE GUT Gut, June 1, 2005; 54(6): 867 - 874. [Full Text] [PDF]

				M. Riewald and W. Ruf Protease-activated Receptor-1 Signaling by Activated Protein C in Cytokine-perturbed Endothelial Cells Is Distinct from Thrombin Signaling J. Biol. Chem., May 20, 2005; 280(20): 19808 - 19814. [Abstract] [Full Text] [PDF]

				L. V. M. Rao and U. R. Pendurthi Tissue Factor-Factor VIIa Signaling Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 47 - 56. [Abstract] [Full Text] [PDF]